FDA Approves Subcutaneous Isatuximab-irfc - Scorecard - MDSpire

FDA Approves Subcutaneous Isatuximab-irfc

The approval expands subcutaneous use across newly diagnosed and previously treated multiple myeloma.

  • By

  • Kathryn Wighton

  • July 10, 2026

  • 2 min

Share

Clinical Scorecard: FDA Approves Subcutaneous Isatuximab-irfc

At a Glance

CategoryDetail
ConditionMultiple Myeloma
Key MechanismsSubcutaneous administration of isatuximab-irfc in combination with other agents.
Target PopulationAdult patients with multiple myeloma
Care SettingOncology

Key Highlights

  • Approved for use in combination with pomalidomide and dexamethasone for patients with prior therapy.
  • Indicated for relapsed or refractory multiple myeloma with carfilzomib and dexamethasone.
  • Approved for newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of multiple myeloma based on clinical and laboratory criteria.

Management

  • Use in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.

Monitoring & Follow-up

  • Monitor for hypersensitivity reactions, neutropenia, infections, and secondary malignancies.

Risks

  • Warnings include hypersensitivity, neutropenia, infections, secondary malignancies, and embryo-fetal toxicity.

Patient & Prescribing Data

Adult patients with multiple myeloma

Recommended dose is 1,400 mg administered subcutaneously.

Clinical Best Practices

  • Utilize the CirCLIQ on-body delivery system or manual administration with a syringe and infusion set.

Related Resources & Content

Original Source(s)

FDA Approves Subcutaneous Isatuximab-irfc

  • by Kathryn Wighton

  • July 10, 2026

Related Content

Accuracy of AI Laryngeal Disorder Detection

Review of 88 studies found AI systems achieved high accuracy for identifying abnormal voices, but performance declined among higher-level laryngeal disorder classifications.

Sugar-Sweetened Beverages May Raise Risk of  Hepatic Cancer Subtypes

In a pooled analysis of more than 1.5 million patients, sugar-sweetened beverages were associated with higher risks of HCC and ICC, while artificially-sweetened beverages showed no independent association with hepatic cancer.

Identity Formation May Shape Residency Emotions

A review of 56 qualitative studies found residents' emotional experiences were influenced by interactions among training demands, workplace relationships, and their evolving professional identity.